Author response for "Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta‐1b in MIRACLE clinical trial"
Faizah Alotaibi(Western University), the Saudi Critical Care Trials Group, Badriah M. AlMutairi(Anna Needs Neuroblastoma Answers), Yaseen M. Arabi(World Health Organization), Ghaleb A. Al Mekhlafi(Riyadh Armed Forces Hospital), Fatehi Elzein(Riyadh Armed Forces Hospital), Naif Khalaf Alharbi(Anna Needs Neuroblastoma Answers), Ziad A. Memish(Alfaisal University), Ahmad Deeb(King Saud bin Abdulaziz University for Health Sciences), Abdulrahman Almasood(King Saud bin Abdulaziz University for Health Sciences), Abdullah M. Assiri(King Khalid University), Steven M. Holland(National Institute of Allergy and Infectious Diseases), Lindsey B. Rosen(National Institute of Allergy and Infectious Diseases), Tlili Barhoumi(King Saud bin Abdulaziz University for Health Sciences), Sarah Al Faraj(King Saud bin Abdulaziz University for Health Sciences), Hanan H. Balkhy(World Health Organization Regional Office for the Eastern Mediterranean), Mashan L. Abdullah(King Saud bin Abdulaziz University for Health Sciences), Yasser Mandourah(Riyadh Armed Forces Hospital), Nisreen Murad Sherbeeni(Riyadh Armed Forces Hospital), Hani Jokhdar(Ministry of Health), Ayed Y. Asiri(Prince Mohammed bin Abdulaziz Hospital), Sameera Aljohani, Shmeylan Al Harbi, Abdulaziz Al‐Dawood, Sameeh Ghazal(Prince Mohammed bin Abdulaziz Hospital), Mohammed W. Alenazi(King Saud bin Abdulaziz University for Health Sciences), Majed Al Jeraisy(King Saud bin Abdulaziz University for Health Sciences), Jesna Jose(King Saud bin Abdulaziz University for Health Sciences)
Cited by 0
Related Papers
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
|Critical Care Medicine|2021|2.8k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k